Suppr超能文献

印度南部地区 COVID-19 相关急性肾损伤的发病率、危险因素和转归研究

Incidence, Risk Factors and Outcome of COVID-19 Associated AKI- A Study from South India.

机构信息

Department of Nephrology, Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu; Corresponding Author.

Department of Nephrology, Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu.

出版信息

J Assoc Physicians India. 2021 Jun;69(6):11-12.

Abstract

BACKGROUND

Acute Kidney Injury (AKI) is a dreaded complication of Covid-19 infection with high morbidity and mortality. Limited data exists on Indian experience. In a tertiary care hospital situated in South India, we analysed the incidence, clinical profile and outcomes of patients diagnosed with AKI due to COVID-19.

METHODS

Retrospective data of Adult cases admitted with COVID-19 over a 8 month period from April - November 2020 was collected. Incidence, Demographics, Clinical profile, Management and Outcomes of COVID-19 associated AKI were analysed. Primary outcome was In- hospital mortality. Secondary outcomes were Dialysis Requirement and Renal Recovery.

RESULTS

52 (7%) out of a total 718 patients with COVID-19 developed AKI. Mean Age was 58 years (IQR 51-69) with a striking male predominance of 92%.(Male:Female -9.4:1) (P< 0.001). Co morbidities seen were Diabetes in 38 (73%) and Hypertension in 31(59%) and Coronary Artery Disease in 17(32%). Fever with myalgia was seen in 29 (46%), Respiratory symptoms in 31(59%), Oliguria in 26(50%) and Diarrhea in 2 (3%) patients. At admission, Hypoxemia and Hypotension were seen in 27 (51%) and 16 (30%) patients respectively. Urinalysis revealed > 2+ dipstick Proteinuria in 24 (46%) and Microscopic hematuria in 16(34%) patients. 25 (48%) were admitted in Stage 3 AKI with a mean S.Creatinine level of 4.4 + 3.4 mg/dl. CT chest showed > 50% lung involvement in 23 patients (44%). Mechanical ventilation was required in 20(38%). Hemodialysis was required in 12 (23%). The median duration of hospitalisation was 10 + 5 days. Primary Outcome of Mortality occurred in 44% of AKI cohort in comparison to 7% in Non AKI cohort (Relative Risk[RR]6.2; 95% Confidence Interval[CI], 4.1 to 9.4) (P= 0.001). Hypoxemia [RR,3.76;95% CI,1.4-9.5], Hypotension [RR 2.54; CI,1.5-4 ], Low Serum albumin [RR1.6;CI,1.1 - 2.3] and Requirement for mechanical ventilation [RR,11.3; CI, 2.9 - 23 ] were significant risk factors for mortality. All 5 patients who required both mechanical ventilation and Dialysis died. 31 patients (59%) were treated with Remdesivir therapy without survival benefit. Significantly higher C-Reactive Protein, Interleukin -6, D-Dimer levels and lower serum albumin levels were seen in those who died. Among the 29 patients who survived, the estimated GFR (e GFR) had recovered in 12 (41%) at discharge. After further followup of 4-6 weeks, the total number of patients who recovered renal function rose to 21 (72%).

CONCLUSION

Mortality in COVID associated AKI stood at 44%. Multiple factors contributed to high mortality such as Severe disease with hypotension and extensive pulmonary involvement, High Neutrophil to Lymphocyte Ratio, Absolute Monocyte Count, inflammatory markers, d-Dimer and low serum albumin. It was encouraging to note that 72% of survivors recovered renal function by 4-6 weeks after discharge from hospital which means that it is worth the struggle to treat AKI in COVID-19.

摘要

背景

急性肾损伤(AKI)是 COVID-19 感染的一种可怕并发症,具有高发病率和死亡率。关于印度的经验,数据有限。在印度南部的一家三级保健医院,我们分析了因 COVID-19 导致 AKI 的患者的发病率、临床特征和结局。

方法

回顾性分析了 2020 年 4 月至 11 月期间 8 个月内因 COVID-19 住院的成年患者的数据。分析了 COVID-19 相关 AKI 的发病率、人口统计学、临床特征、管理和结局。主要结局是院内死亡率。次要结局是透析需求和肾功能恢复。

结果

在总共 718 例 COVID-19 患者中,有 52 例(7%)发生 AKI。平均年龄为 58 岁(IQR 51-69),男性占 92%(男:女为 9.4:1)(P<0.001)。合并症为糖尿病 38 例(73%)、高血压 31 例(59%)和冠心病 17 例(32%)。29 例(46%)有发热伴肌痛,31 例(59%)有呼吸道症状,26 例(50%)有少尿,2 例(3%)有腹泻。入院时,27 例(51%)患者有低氧血症,16 例(30%)患者有低血压。尿液分析显示 24 例(46%)有>2+ 尿蛋白和 16 例(34%)有镜下血尿。25 例(48%)为 AKI 3 期,平均血肌酐水平为 4.4+3.4mg/dl。胸部 CT 显示 23 例(44%)有>50%的肺部受累。20 例(38%)需要机械通气。12 例(23%)需要血液透析。中位住院时间为 10+5 天。AKI 组的主要结局死亡率为 44%,而非 AKI 组为 7%(相对风险[RR]6.2;95%置信区间[CI],4.1-9.4)(P=0.001)。低氧血症(RR,3.76;95%CI,1.4-9.5)、低血压(RR 2.54;CI,1.5-4)、低血清白蛋白(RR 1.6;CI,1.1-2.3)和需要机械通气(RR,11.3;CI,2.9-23)是死亡的显著危险因素。所有需要机械通气和透析的 5 例患者均死亡。31 例(59%)患者接受了瑞德西韦治疗,但无生存获益。死亡患者的 C 反应蛋白、白细胞介素-6、D-二聚体水平显著升高,血清白蛋白水平显著降低。在 29 例存活患者中,12 例(41%)在出院时估计肾小球滤过率(eGFR)恢复。进一步随访 4-6 周后,肾功能恢复的患者总数增加到 21 例(72%)。

结论

COVID 相关 AKI 的死亡率为 44%。低血压和广泛的肺部受累等严重疾病、高中性粒细胞与淋巴细胞比值、绝对单核细胞计数、炎症标志物、D-二聚体和低血清白蛋白等多种因素导致死亡率较高。令人鼓舞的是,出院后 4-6 周,21 例(72%)幸存者的肾功能恢复,这意味着治疗 COVID-19 相关 AKI 是值得的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验